Ascendis Pharma (NASDAQ: ASND) completes move from ADSs to ordinary shares

Rhea-AI Filing Summary

Ascendis Pharma A/S has shifted its Nasdaq presence from American Depositary Shares to directly listed ordinary shares. The ordinary shares began trading on the Nasdaq Global Select Market under the ticker ASND on April 20, 2026.

The company implemented a mandatory exchange in which each outstanding ADS was converted into one ordinary share listed on Nasdaq. The last trading day for ADSs was April 17, 2026, and by April 20, 2026 all ADSs had been exchanged for ordinary shares.

Key Figures

Start of ordinary share trading: April 20, 2026 Last ADS trading day: April 17, 2026 ADS to ordinary share ratio: 1 ADS : 1 ordinary share

3 metrics

Start of ordinary share trading April 20, 2026 Ordinary shares began trading on Nasdaq Global Select Market

Last ADS trading day April 17, 2026 Final day Ascendis ADSs traded on Nasdaq

ADS to ordinary share ratio 1 ADS : 1 ordinary share Mandatory exchange of all outstanding ADSs

Key Terms

American Depositary Shares, Nasdaq Global Select Market, ordinary shares, Form S-8, +1 more

5 terms

American Depositary Shares financial

"replacing the listing of American Depositary Shares (“ADSs”)."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Nasdaq Global Select Market financial

"trading of its ordinary shares on The Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

ordinary shares financial

"the commencement of trading of its ordinary shares on The Nasdaq Global Select Market"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form S-8 regulatory

"incorporated by reference into the registration statements on Form S-8"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

Form F-3 regulatory

"incorporated by reference into the registration statements on Form S-8 ... and Form F-3"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Translation of registrant’s name into English)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

On April 20, 2026, the Company announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (“Nasdaq”), replacing the listing of American Depositary Shares (“ADSs”).

The ordinary shares trade under the same ticker symbol “ASND” as previously used for the ADS listing. The ordinary shares trade under CUSIP number K08588103 and ISIN DK0060606333.

On April 8, 2026, the Company announced plans to mandatorily exchange all outstanding ADSs for ordinary shares, with each ADS exchangeable for one ordinary share listed on Nasdaq. The last trading day for ADSs on Nasdaq was April 17, 2026. As of April 20, 2026, all outstanding ADSs were exchanged for ordinary shares.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: April 20, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

FAQ

What did Ascendis Pharma (ASND) announce in this Form 6-K?

Ascendis Pharma announced that its ordinary shares began trading on the Nasdaq Global Select Market, replacing its American Depositary Shares. The company also confirmed completion of a mandatory exchange of all outstanding ADSs for ordinary shares listed on Nasdaq on a one-for-one basis.

When did Ascendis Pharma ordinary shares start trading on Nasdaq?

Ascendis Pharma’s ordinary shares started trading on the Nasdaq Global Select Market on April 20, 2026. This new listing replaces the prior Nasdaq listing of American Depositary Shares and continues under the same ticker symbol, ASND, for continuity in market trading.

What was the exchange ratio for Ascendis Pharma ADSs to ordinary shares?

Each Ascendis Pharma American Depositary Share was mandatorily exchanged for one ordinary share listed on Nasdaq. This one-for-one exchange ratio means existing ADS holders received an equal number of ordinary shares, keeping their numerical holdings consistent through the conversion.

When was the last trading day for Ascendis Pharma ADSs on Nasdaq?

The last trading day for Ascendis Pharma American Depositary Shares on Nasdaq was April 17, 2026. After that date, ADSs ceased trading, and by April 20, 2026, all outstanding ADSs had been fully exchanged into ordinary shares listed on Nasdaq.

Does Ascendis Pharma keep the same ticker symbol after moving to ordinary shares?

Yes. After moving from American Depositary Shares to directly listed ordinary shares on the Nasdaq Global Select Market, Ascendis Pharma continues to trade under the same ticker symbol, ASND, helping maintain continuity and recognition for existing and prospective investors.

How is this Form 6-K incorporated into Ascendis Pharma’s U.S. registrations?

This Form 6-K is incorporated by reference into Ascendis Pharma’s existing Form S-8 and Form F-3 registration statements. That means the information here becomes part of those registered offerings and related prospectuses, unless later filings or reports supersede it.